Medical City Plano’s $107 million Sarah Cannon Cancer Hospital opens Monday, adding to Medical City Healthcare’s hospital network in North Texas. Sarah Cannon is the cancer institute of Medical City’s parent company HCA Healthcare, and the facility will be the first Sarah Cannon facility in Texas.
“This is an important milestone in the larger collaboration between Medical City Healthcare and Sarah Cannon, the Cancer Institute of our parent company HCA Healthcare,” says Erol Akdamar, FACHE, president of Medical City Healthcare via release. “While the name is new to North Texas, the expertise of Sarah Cannon and Medical City Healthcare is established. Working together, we leverage the breadth and depth of our expertise and resources – redefining how cancer care is delivered in the communities we serve.”
Sarah Cannon offers integrated cancer treatment for patients across the HCA system, and is named for the television and entertainer who portrayed “Minnie Pearl” at the grand Ole Opry in Nashville and on the show “Hee Haw” for over 50 years. She offered the use of her name after her successful breast cancer treatment in Nashville. The cancer program includes patient navigation from oncology-trained nurses, stem cell transplants, clinical trials, and molecular profiling capabilities.
The new hospital will be part of the 513-bed Medical City Plano campus, and will have 90 additional patient beds, operating rooms, and recovery rooms in the 138,000 square feet space, which will also include a new burn and trauma ICU unit. It is part of a $1.8 billion investment into the Medical City system, which includes new heart and spine hospitals and other improvements in North Texas.
“We are proud to partner with Medical City Healthcare to advance cancer care in North Texas,” said Fred LeMaistre, MD, Senior Vice President of Market Operations & Physician-in-Chief of Blood Cancers, Sarah Cannon via release. “Our partnership is built on the strength of locally-trusted care provided by a globally-recognized oncology network with access to leading-edge, life-saving therapies.”
